

IMPAACT Annual Meeting

Priorities for HIV Research, Moving Ahead Through Partnerships

Carl W. Dieffenbach, Ph.D.
Director, Division of AIDS

June 22, 2021



National Institute of
Allergy and
Infectious Diseases

June 5, 1981

Pneumocystis Pneumonia – Los Angeles

July 3, 1981

Kaposi's Sarcoma and Pneumocystis Pneumonia Among Homosexual Men – New York City and California

CENTERS FOR DISEASE CONTROL



MORBIDITY AND MORTALITY WEEKLY REPORT

December 17, 1982 / 31(49);665-667


**Unexplained Immunodeficiency and
Opportunistic Infections in Infants – New
York, New Jersey, California**

December 10, 1982 / 31(48);652-654


**Epidemiologic Notes and Reports Possible
Transfusion-Associated Acquired Immune
Deficiency Syndrome (AIDS) – California**


HIV Structure and Genes


Organization of the HIV-1 Virion



HIV Genomic Map







What Has Changed in the Last 10 Years?

- **Better medications**
- **Understanding ART → U=U**
- **Choices for HIV prevention**
- **Hepatitis C medications**
- **New TB medications, shortened treatment regimens**
- **Progress on TB vaccines, chemoprophylaxis for PLWH**
- **Progress in development of pediatric formulations**
Dolutegravir, Raltegravir (INSTIs) and Etravirine (NNRTI)



National Institute of Allergy and Infectious Diseases

Leading research to understand, treat, and prevent infectious, immunologic, and allergic diseases.

FOR IMMEDIATE RELEASE
Monday, November 30, 2020

NIAID Announces Newly Funded HIV/AIDS Clinical Trials Networks

Awards Will Run Through 2027



NIH/NIAID/DAIDS Priorities

For IMPAACT, addressing the therapeutic needs across the life span with emphasis on key populations

The NIH Strategic Plan for HIV Research, Collaborations

- **Reduce the Incidence of HIV Therapies (Vaccines with HVTN)**
 - **Conduct Research Toward HIV Cure (Collaboratories, Therapeutic Vaccines and bNAbs, ACTG)**
 - **Address Tb as the primary HIV-associated Co-infection
Neurocognitive/neurological effects as the primary comorbidity**
 - **Advance Cross-cutting Areas of Research relevant to the key populations**
- **Cross-cutting Areas of Research:**
 - Basic Virology and Immunology
 - Behavioral and Social Sciences
 - Epidemiology
 - Health Disparities
 - Information Dissemination
 - Implementation Science
 - Research Training, Infrastructure, and Capacity Building

Select Ongoing/Planned IMPAACT Studies for ARV and TB Drugs

- **Ongoing studies with planned/upcoming registrational filing:**
 - IMPAACT 2014, 2017, 2019, 2032
- **Registrational studies planned/in development:**
 - IMPAACT 2023, 2029, 2036, 2034, others
- **Non-registrational studies that will provide data to inform guidelines:**
 - IMPAACT 2026, P1108, others
- **Need to assess the timing of when to begin these. Need to get a sustainable cadence to the trials**

Questions?